Get the Stockscreener App
0.2354
7.07%
-0.0179
After Hours:
.23
-0.0054
-2.29%
Theriva Biologics Inc stock is traded at $0.2354, with a volume of 37.22M.
It is down -7.07% in the last 24 hours and down -7.76% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.2533
Open:
$0.2997
24h Volume:
37.22M
Relative Volume:
1.94
Market Cap:
$10.80M
Revenue:
-
Net Income/Loss:
$-21.46M
P/E Ratio:
-0.093
EPS:
-2.5324
Net Cash Flow:
$-14.40M
1W Performance:
-5.92%
1M Performance:
-7.76%
6M Performance:
+5.70%
1Y Performance:
-45.27%
1-Day Range:
$0.2279
$0.2997
1-Week Range:
$0.2279
$0.2997
52-Week Range:
$0.1628
$0.8632
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.2354 | 11.62M | 0 | -21.46M | -14.40M | -2.5324 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Theriva Biologics Inc Stock (TOVX) Latest News
Theriva Biologics (TOVX) Secures Approval for VIRAGE2 Clinical T - GuruFocus
Theriva Biologics launches VIRAGE2 metastatic pancreatic trial - TipRanks
Theriva Biologics cleared to start VIRAGE2 trial | TOVX 8-K Filing - Stock Titan
Theriva Biologics receives approval to start VIRAGE2 cancer trial By Investing.com - Investing.com Canada
Theriva wins Spain nod for more frequent VCN-01 dosing in pancreatic cancer trial - Stock Titan
Theriva Biologics (TOVX) Holds Steady Near Support After Modest GainRetracement Entry - dars.gov.et
Form DEF 14A THERIVA BIOLOGICS For: 29 June By Investing.com - Investing.com Nigeria
Theriva Biologics (NYSE American: TOVX) puts large share and warrant proposals to vote - Stock Titan
Enterprise value to EBIT forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Price to book forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Enterprise value to EBIT forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView
Enterprise value to EBITDA forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView
Enterprise value to revenue forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView
Price to sales forward of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Price to earnings forward of Theriva Biologics, Inc. – FWB:SFY0 - TradingView
Theriva Biologics Company Profile & Introduction - Moomoo
Theriva Biologics, Inc. Actuals & Estimates (AMEX:TOVX) - TradingView
TOVX Forecast — Price Target — Prediction for 2027 - TradingView
Theriva Biologics, Inc. Actuals & Estimates (FWB:SFY0) - TradingView
SFY0 Forecast — Price Target — Prediction for 2027 - TradingView
Theriva Biologics Inc (TOVX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Theriva Biologics (TOVX) Proxy filing Summary - Quartr
Theriva Biologics Inc (TOVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TOVX Should I Buy - Intellectia AI
Theriva Biologics Inc (TOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Theriva Biologics Inc (TOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Theriva Biologics (TOVX) asks shareholders to approve share, plan and warrant changes - Stock Titan
Theriva Biologics Inc (TOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Theriva Biologics Inc (TOVX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Theriva Biologics Inc (TOVX) Institutional Confidence - TradingKey
Theriva Biologics Inc (TOVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Theriva Biologics Inc (TOVX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Why is Theriva stock gaining Monday? - MSN
Theriva Biologics (TOVX) Surges Over 26%: Key Levels to Watch After BreakoutCall Resistance - newsline.com
Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention - TechStock²
Theriva Biologics reports survival data from VCN-01 cancer trial - Investing.com
Theriva Biologics highlights promising VCN-01 Phase 1 results - TipRanks
$Theriva Biologics (TOVX.US)$ - Moomoo
Theriva Biologics (NYSE American: TOVX) shares VCN-01 Phase 1 head and neck cancer data - Stock Titan
Small trial: virus-immunotherapy combo linked to longer survival in head and neck cancer - Stock Titan
TOVX Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesOperating Margin Analysis - newsline.com
Theriva Biologics Faces Quorum Issue Delaying Warrant Vote - TipRanks
Theriva Biologics (NYSE: TOVX) fails quorum, delays 16.18M-warrant share vote - Stock Titan
MSN Money - MSN
Number of shareholders of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Theriva Biologics (TOVX) Slides 8% as Stock Tests Key Support at $0.27Dark Pool Sentiment - The Legal Advocate
Theriva Biologics (TOVX) Faces Pressure: Stock Slides 8% as Key Support Levels Are TestedLeveraged ETF Flow - The Legal Advocate
Theriva Biologics (TOVX) Advances 4.99% as Stock Approaches Key Resistance at $0.33McClellan Oscillator - newsline.com
Theriva Biologics (TOVX) Gains Nearly 5% as Stock Attempts to Recover Key Support LevelsAI Trade Signals - The Legal Advocate
TOVXTheriva Biologics Inc Stock Price and Quote - Finviz
Theriva Biologics (TOVX) Slides 5.73% as Price Nears Critical Support at $0.28BPI Reversal - The Legal Advocate
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Cap:
|
Volume (24h):